


AUC Airway Resistance
Airway Resistance (AUC)
3000
2500
2000
1500
1000
500
0
(n=7-8)
***
*
Saline
OVA
GLA-AF
(2 µg)

FIGURE 1A


AUC Dynamic Lung Compliance
Lung Compliance (AUC)
0
-500
-600
-800
-1000
-1200
(n=7-8)
***
††
Saline
OVA
GLA-AF
(2 µg)




FIGURE 2A




FIGURE 2B




FIGURE 2C



OVA Specific Sera IgE
Saline
OVA
OVA-GLA
OVA Specific IgE [ng/ml]
0
1
2
3
4
5
6
7
8
Before Sensitization
Day -4
Before Challenge
Day +16
After Challenge
Day +21

FIGURE 3




FIGURE 4A




FIGURE 4B




FIGURE 4C




FIGURE 4D




FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 6C




FIGURE 6D

Ascaris-Induced Reduction in Nasal Minimum Cross-sectional Area (24hr, 2 and 4 weeks after 4th dose)




FIGURE 7A

Ascaris-Induced Reduction in Nasal Volume (24hr, 2 and 4weeks after 4th dose)





FIGURE 7B



* P<0.05 vs Vehicle. Mixed effects ANOVA. Means +/- Standard Error

FIGURE 7C




FIGURE 8A




FIGURE 8B




FIGURE 8C




FIGURE 8D




FIGURE 9




FIGURE 10A




FIGURE 10B




FIGURE 10C




FIGURE 11A




FIGURE 11B




FIGURE 11C




FIGURE 11D

- 12 male cynomolgus NHPs
  - Naturally allergic to *Ascaris suum*
- 3 treatment groups (Latin crossover design):

	GLA Adjuvant	Ag Route	Rhinometry
SE	IM	IM	No
GLA-SE	IM	IN	No
GLA-SE	IM	IM	Yes
GLA-AF	IN	IN	Yes

- Compound + Ag once weekly for 4 weeks
- Intra-nasal Ascaris challenge at:
  - 24 hours, 2 weeks & 4 weeks
  - After final dose
- Ascaris-induced nasal congestion measured using rhinometery

FIGURE 12A




FIGURE 12B



Sensitization (RoastedPPE 1mg/5 mg Alum, IP)
D-0
D-7
D-14
GLA-SE (2 µg, SC/IM/PO)
R-PPE challenge
(12 mg, i.p.)
D-20
D-21
ENDPOINTS
Anaphylaxis/body temperature
assessed 40 min post challenge
Anaphylaxis Score (0 - 5)
Day 21 score
SE Vehicle (SC)
GLA-SE 2.0 µg (SC)
SE Vehicle (PO)
GLA-SE 2.0 µg (PO)
SE Vehicle (IM)
GLA-SE 2.0 µg (IM)
Δ Core body temperature (°C)
SE Vehicle (SC)
GLA-SE 2.0 µg (SC)
SE Vehicle (PO)
GLA-SE 2.0 µg (PO)
SE Vehicle (IM)
GLA-SE 2.0 µg (IM)

FIGURE 13




FIGURE 14A




FIGURE 14B




FIGURE 14C




FIGURE 14D




FIGURE 14E




FIGURE 15A




FIGURE 15B




FIGURE 16A




FIGURE 16B




FIGURE 16C




FIGURE 16D